COVID-19 Huashi Baidu Formula Clinical Study

Launched by XIYUAN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Dec 5, 2022

Keywords

ClinConnect Summary

The COVID-19 Huashi Baidu Formula Clinical Study is looking to evaluate a treatment called Huashi Baidu Granule for people with mild to moderate COVID-19. This study is specifically focusing on patients in Asia and Africa to see how effective and safe this treatment is. Researchers want to understand how the formula works and if it can help improve the health of those infected with the virus.

To participate in the trial, you need to be between 18 and 65 years old, have been diagnosed with mild to moderate COVID-19 within the last five days, and be able to follow the treatment plan. However, if you have severe respiratory issues, are pregnant, or have certain other health conditions, you may not be eligible. If you decide to join, you will be asked to sign an informed consent form, which means you agree to participate after being informed about the study. Participants will receive the treatment and will be monitored for its effects. This is an opportunity to contribute to research that may help improve future COVID-19 treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Conform to the diagnostic criteria for COVID-19 mild and moderate in the Guidelines for the Diagnosis and Treatment of Novel Coronavirus (COVID-19) Infection (Trial Version 10) ；
• • 2. Age ≥ 18 years and ≤ 65 years;
• • 3. The time from the first symptom (or confirmed onset) shall not exceed 5 days;
• • 4. If the patient agrees to participate in the study, he/she will sign the informed consent form through paper signature, electronic signature of mobile software or voice authorization.
• Exclusion Criteria:
• • 1. Patients who cannot guarantee the compliance of taking medicine during the treatment period, and who are difficult to take medicine by oral or nasal feeding.
• • 2. Patients with severe primary respiratory diseases or other pathogenic microorganism pneumonia that needs to be differentiated from COVID-19.
• • 3. Pregnant women, with positive urine pregnancy test, or with pregnancy plan within 12 months.
• • 4. Patients suffering from malignant tumors, mental diseases and other systematic malignant diseases that the researchers consider unsuitable for the study.
• • 5. People who have ever been allergic to the test drug and who do not tolerate the drug.
• • 6. Those who are participating in other clinical trials.
• • 7. Non severe patients in the trial shall not enter the study again after changing the classification.